MX369360B - ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I). - Google Patents

ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).

Info

Publication number
MX369360B
MX369360B MX2015013402A MX2015013402A MX369360B MX 369360 B MX369360 B MX 369360B MX 2015013402 A MX2015013402 A MX 2015013402A MX 2015013402 A MX2015013402 A MX 2015013402A MX 369360 B MX369360 B MX 369360B
Authority
MX
Mexico
Prior art keywords
osteogenesis imperfecta
methods
treating
treating osteogenesis
subject
Prior art date
Application number
MX2015013402A
Other languages
English (en)
Other versions
MX2015013402A (es
Inventor
T Sampath Kuber
Lee Brendan
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369360(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2015013402A publication Critical patent/MX2015013402A/es
Publication of MX369360B publication Critical patent/MX369360B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar y mejorar los síntomas de la osteogénesis imperfecta (OI) en un sujeto administrando al sujeto una cantidad terapéuticamente eficaz de un agente de unión que se une a factor de crecimiento transformante beta (TGFß).
MX2015013402A 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I). MX369360B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361803647P 2013-03-20 2013-03-20
US201361875399P 2013-09-09 2013-09-09
US201361883151P 2013-09-26 2013-09-26
PCT/US2014/031279 WO2014153435A1 (en) 2013-03-20 2014-03-20 Methods for treating osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
MX2015013402A MX2015013402A (es) 2016-01-08
MX369360B true MX369360B (es) 2019-11-06

Family

ID=50483613

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).
MX2019009122A MX2019009122A (es) 2013-03-20 2015-09-18 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009122A MX2019009122A (es) 2013-03-20 2015-09-18 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Country Status (27)

Country Link
US (4) US9598486B2 (es)
EP (3) EP2976359B2 (es)
JP (3) JP6483086B2 (es)
KR (1) KR102257138B1 (es)
CN (2) CN111000997A (es)
AU (1) AU2014235933B2 (es)
CA (1) CA2907422C (es)
CL (1) CL2015002801A1 (es)
DK (2) DK3312195T3 (es)
EA (1) EA032327B1 (es)
ES (2) ES2763869T3 (es)
HK (2) HK1213576A1 (es)
HR (2) HRP20181939T4 (es)
HU (1) HUE046702T2 (es)
IL (2) IL241461B (es)
LT (2) LT2976359T (es)
MX (2) MX369360B (es)
MY (1) MY172324A (es)
PH (2) PH12015501864A1 (es)
PL (2) PL3312195T3 (es)
PT (2) PT3312195T (es)
RS (2) RS58188B2 (es)
SG (2) SG10201701985YA (es)
SI (2) SI2976359T2 (es)
TW (1) TWI629995B (es)
UY (1) UY35493A (es)
WO (1) WO2014153435A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3312195T (pt) * 2013-03-20 2019-12-23 Baylor College Medicine Métodos de tratamento de osteogénese imperfeita
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
CN106755395B (zh) * 2016-12-16 2020-05-12 山东第一医科大学(山东省医学科学院) Xi型成骨不全致病基因fkbp10的突变位点及其应用
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
EP3571227A1 (en) * 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
US20190248881A1 (en) * 2017-12-04 2019-08-15 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
AU2019301283A1 (en) 2018-07-10 2021-02-04 Sanofi Combination therapies against cancer targeting CD38 and TGF-beta
KR20230112629A (ko) * 2020-10-23 2023-07-27 에이치큐 한 종양괴사인자-알파 및 형질전환성장인자-베타의 이작용성 길항제 및 이의 용도
EP4334347A1 (en) * 2021-05-07 2024-03-13 Baylor College of Medicine Treatment of moderate-to-severe osteogenesis imperfecta
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
WO2023077131A1 (en) * 2021-11-01 2023-05-04 Genzyme Corporation Treatment of osteogenesis imperfecta

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6716836A (es) * 1967-12-11 1969-06-13
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2352532C (en) * 1998-11-27 2014-10-14 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
DK1850873T3 (en) * 2005-02-08 2019-03-18 Genzyme Corp ANTIBODIES AGAINST TGF-BETA
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
TWI667038B (zh) * 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
JP2010528586A (ja) * 2007-04-26 2010-08-26 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨形成及び鉱化作用を調節する化合物の同定のためのアッセイ
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EA201001162A1 (ru) * 2008-01-15 2010-12-30 Калобиос Фармасьютикалс, Инк. Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf
EP2421559B1 (en) * 2009-04-24 2016-07-20 Vanderbilt University Anti-tgf-beta induction of bone growth
PT3312195T (pt) * 2013-03-20 2019-12-23 Baylor College Medicine Métodos de tratamento de osteogénese imperfeita

Also Published As

Publication number Publication date
KR102257138B1 (ko) 2021-05-26
HRP20192277T1 (hr) 2020-03-06
WO2014153435A1 (en) 2014-09-25
CA2907422A1 (en) 2014-09-25
CN111000997A (zh) 2020-04-14
PL2976359T3 (pl) 2019-03-29
EP2976359B1 (en) 2018-08-29
LT2976359T (lt) 2018-12-27
MX2019009122A (es) 2019-09-16
BR112015023905A2 (pt) 2017-10-24
CN105229028A (zh) 2016-01-06
US20160031979A1 (en) 2016-02-04
PH12015501864B1 (en) 2015-12-07
JP2019089826A (ja) 2019-06-13
NZ712353A (en) 2021-04-30
CN105229028B (zh) 2019-11-08
MY172324A (en) 2019-11-21
IL241461A0 (en) 2015-11-30
PH12019500261B1 (en) 2020-07-20
HRP20181939T1 (hr) 2019-01-25
EA032327B1 (ru) 2019-05-31
AU2014235933B2 (en) 2019-01-24
RS58188B2 (sr) 2022-06-30
IL287915A (en) 2022-01-01
TWI629995B (zh) 2018-07-21
ES2700238T3 (es) 2019-02-14
DK2976359T4 (da) 2022-06-13
DK2976359T3 (da) 2019-01-02
EP3312195B1 (en) 2019-10-09
SI2976359T2 (sl) 2022-05-31
SG10201701985YA (en) 2017-04-27
JP2016519093A (ja) 2016-06-30
PL3312195T3 (pl) 2020-04-30
TW201524515A (zh) 2015-07-01
EA201591843A1 (ru) 2016-01-29
DK3312195T3 (da) 2020-01-06
EP3640260A1 (en) 2020-04-22
KR20150132262A (ko) 2015-11-25
HK1213576A1 (zh) 2016-07-08
IL241461B (en) 2021-12-01
RS58188B1 (sr) 2019-03-29
EP3312195A1 (en) 2018-04-25
PH12015501864A1 (en) 2015-12-07
CA2907422C (en) 2021-08-31
JP7016113B2 (ja) 2022-02-04
SI3312195T1 (sl) 2020-02-28
JP2020109110A (ja) 2020-07-16
HRP20181939T4 (hr) 2022-05-13
US20190389943A1 (en) 2019-12-26
EP2976359A1 (en) 2016-01-27
US10377819B2 (en) 2019-08-13
US11230595B2 (en) 2022-01-25
PT2976359T (pt) 2018-12-05
HK1253717A1 (zh) 2019-06-28
CL2015002801A1 (es) 2016-08-12
UY35493A (es) 2014-11-28
PT3312195T (pt) 2019-12-23
JP6483086B2 (ja) 2019-03-13
RS59673B1 (sr) 2020-01-31
ES2763869T3 (es) 2020-06-01
MX2015013402A (es) 2016-01-08
US9598486B2 (en) 2017-03-21
US20220195025A1 (en) 2022-06-23
PH12019500261A1 (en) 2020-07-20
EP2976359B2 (en) 2022-03-23
JP6677837B2 (ja) 2020-04-08
HUE046702T2 (hu) 2020-03-30
SI2976359T1 (sl) 2019-03-29
SG11201506683XA (en) 2015-09-29
US20170247439A1 (en) 2017-08-31
AU2014235933A1 (en) 2015-10-01
LT3312195T (lt) 2020-01-10
ES2700238T5 (es) 2022-05-20
PL2976359T5 (pl) 2022-07-18

Similar Documents

Publication Publication Date Title
PH12019500261A1 (en) Methods for treating osteogenesis imperfecta
PH12015502075A1 (en) Treatment of cataplexy
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2015017970A (es) Metodos para tratar la poliposis nasal mediante la administracion de un antagonista de il-4r.
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
MX2013012572A (es) Anticuerpos anti-cd40 y metodos de uso.
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
GB201112145D0 (en) Means and methods for the treatment of pathological angiogenesis
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
MX354989B (es) Regimenes de tratamiento.
IN2014DN07989A (es)
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
AR095700A1 (es) Métodos para el tratamiento de la osteogénesis imperfecta
MX2013006633A (es) Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes.
WO2013158698A3 (en) Method treating scleroderma
WO2014151230A3 (en) Method of treating granulomatosis with polyangiitis
IN2013MU02486A (es)

Legal Events

Date Code Title Description
FG Grant or registration